Difference between revisions of "Rilzabrutinib (PRN-1008)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: BTK inhibitor <br>Route: PO <br>Extravasation: n/a ==Preliminary data== ===Immune thrombocytopenia=== #'''PRN1008-010:''' Kuter D...") |
Warner-admin (talk | contribs) m (Text replacement - " (NCT[0-9]{8})" to " https://clinicaltrials.gov/ct2/show/$1") |
||
Line 6: | Line 6: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Immune thrombocytopenia]]=== | ===[[Immune thrombocytopenia]]=== | ||
− | #'''PRN1008-010:''' Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. [https://doi.org/10.1056/nejmoa2110297 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35417637/ PubMed] NCT03395210 | + | #'''PRN1008-010:''' Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. [https://doi.org/10.1056/nejmoa2110297 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35417637/ PubMed] https://clinicaltrials.gov/ct2/show/NCT03395210 |
==Also known as== | ==Also known as== |
Revision as of 12:51, 6 June 2023
General information
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
Preliminary data
Immune thrombocytopenia
- PRN1008-010: Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. link to original article PubMed https://clinicaltrials.gov/ct2/show/NCT03395210
Also known as
- Code name: PRN-1008